A Clinical Study of Arfolitixorin in Patients With mCRC

This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study. There is already a standard therapy for treatment of colorectal cancer. This therapy contains a combination of the medicines leucovorin, fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab. The sponsoring company is developing the new therapy called arfolitixorin. In this study, patients with colorectal cancer will be given arfolitixorin instead of th

Trial Details

NCT ID
NCT06922383
Phase
PHASE1 / PHASE2
Sponsor
Isofol Medical AB
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • arfolitixorin (ARFOX + bevacizumab)
Locations (sample)
  • Berlin, Germany|52.52437,13.41053
  • Essen, Germany|51.45657,7.01228
  • München, Germany|51.60698,13.31243

Key Eligibility Criteria

  • Signed ICF and ability to comply with protocol requirements.
  • Phase 1b: Histologically confirmed RAS mutant, MSS/pMMR, colorectal adenocarcinoma with metastatic disease, eligible for first-line therapy with 5-…
  • Histologically confirmed, colorectal adenocarcinoma with metastatic disease, eligible for first-line therapy with 5-FU based backbones, i.e.:
  • Patients with mutated RAS who are candidates for therapy with FOLFOX or FOLFIRI plus bevacizumab.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →